VEGFA and ovarian carcinoma: However, paclitaxel has shown synergistic interaction with various classes of targeted therapeutic agents (eg anti‐VEGF inhibitors and PARP inhibitors) and is currently being assessed in adjuvant and neo‐adjuvant treatment settings for ovarian cancer.40 Interestingly, BBI608 can enhance paclitaxel sensitivity in A2780 and SKOV3 cells at a low concentration of 1nM in a synergistical manner.